Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2‐year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
| Autor: | Ricardo P. Casaroli-Marano, Pierre-Henry Gabrielle, Lucia Miguel, Socorro Alforja, Daniel Barthelmes, Jennifer J. Arnold, Javier Zarranz-Ventura, Laura Sararols, Mark C Gillies, Catherine Creuzot-Garcher, Vuong Nguyen |
|---|---|
| Přispěvatelé: | The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia, Service d'Ophtalmologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospital Clinic Barcelona, Hospital General de Catalunya, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Marsden Eye Research - Marsden Eye Specialists, University hospital of Zurich [Zurich], La fondation de France., University of Zurich, Gabrielle, Pierre-Henry |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A genetic structures Treatment outcome Visual Acuity Angiogenesis Inhibitors Blindness chemistry.chemical_compound 0302 clinical medicine Ceguesa Registries Fluorescein Angiography high myopia Factor de creixement de l'endoteli vascular Incidence General Medicine Middle Aged 2731 Ophthalmology myopic choroidal neovascularization 3. Good health Bevacizumab Clinical Practice Vascular endothelial growth factor Treatment Outcome Intravitreal Injections Myopia Degenerative Female Tomography Optical Coherence medicine.drug 10018 Ophthalmology Clinic medicine.medical_specialty Fundus Oculi VEGF inhibitors 610 Medicine & health Caucasian White People 03 medical and health sciences Myopic choroidal neovascularization Vascular endothelial growth factors Ranibizumab Ophthalmology medicine Humans myopia [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs Aged Retrospective Studies optical coherence tomography business.industry Retinal medicine.disease Choroidal Neovascularization eye diseases pathological myopia chemistry 030221 ophthalmology & optometry anti-VEGF therapy sense organs business 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Acta Ophthalmologica Scandinavica-Supplement Acta Ophthalmologica Scandinavica-Supplement-, In press, ⟨10.1111/aos.14893⟩ Dipòsit Digital de la UB Universidad de Barcelona |
| ISSN: | 1395-3931 |
| DOI: | 10.1111/aos.14893⟩ |
| Popis: | Purpose: To report the 24-month outcomes of vascular endothelial growth factor (VEGF) inhibitors for myopic choroidal neovascularization (mCNV) in predominantly Caucasian eyes in routine clinical practice. Methods: Retrospective analysis of treatment-na¿ıve eyes starting intravitreal injection of VEGF inhibitors of either bevacizumab (1.25 mg) or ranibizumab (0.5 mg) for mCNV from 1 January 2006 to 31 May 2018 that were tracked in the Fight Retinal Blindness! registry. Results: We identified 203 eyes (bevacizumab-85 and ranibizumab-118) of 189 patients. The estimated mean (95% CI) change in VA over 24 months for all eyes using longitudinal models was +8 (5, 11) letters with a median (Q1, Q3) of 3 (2, 5) injections given mostly during the first year. The estimated mean change in VA at 24 months was similar between bevacizumab and ranibizumab [+9 (5, 13) letters for bevacizumab versus +9 (6, 13) letters for ranibizumab; p = 0.37]. Both agents were also similar in the mCNV activity outcomes, treatment frequency and visit frequency. Conclusions: The 24-month treatment outcomes of VEGF inhibitors for mCNV were favourable in this largest series yet reported of predominantly Caucasian eyes in routine clinical practice,with approximately two lines of visual gain and amedian of three injections given mostly during the first year. These outcomes are similar to those reported for predominantly Asian eyes.Bevacizumab appeared to be as safeandeffective as ranibizumab. Key words: anti-VEGF therapy - Caucasian - high myopia - myopia - myopic choroidal neovascularization - optical coherence tomography - pathologic myopia - VEGF inhibitors |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|